Treatment with anti-vegf antibodies

Abstract

This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.

1 . A method of treating metastatic ovarian cancer in a human patient, comprising administering to the patient effective amounts of an anti-VEGF antibody and an anti-neoplastic composition, wherein said anti-neoplastic composition comprises at least one chemotherapeutic agent and wherein said anti-VEGF antibody is bevacizumab.  
   
   
       2 . The method of  claim 1 , wherein the anti-VEGF antibody is administered concomitantly with the at least one chemotherapeutic agent.  
   
   
       3 . The method of  claim 1 , wherein the patient is previously untreated.  
   
   
       4 . The method of  claim 1 , wherein the chemotherapeutic agent is selected from the group consisting of 5-fluorouricil, leucovorin, irinotecan, oxaliplatin, capecetabine, paclitaxel and doxetaxel.  
   
   
       5 . The method of  claim 4 , wherein the chemotherapeutic agent additionally comprises a platinum coordination complex.  
   
   
       6 . The method of  claim 5 , wherein the chemotherapeutic agent is paclitaxel.  
   
   
       7 . The method of  claim 6 , wherein the platinum coordination complex is carboplatin.  
   
   
       8 . The method of  claim 1 , wherein the anti-VEGF antibody is administered intravenously.  
   
   
       9 . The method of  claim 8 , wherein the anti-VEGF antibody is administered to the patient at about 5 mg/kg to about 15 mg/kg every 2 to 3 weeks.  
   
   
       10 . The method of  claim 9 , wherein the anti-VEGF antibody is administered by intravenous infusion over 30-90 minutes.  
   
   
       11 . The method of  claim 10 , wherein the anti-VEGF antibody is administered to the patient at 15 mg/kg every 3 weeks.